Last Updated : February 25, 2020
Details
Generic Name:
pembrolizumab
Project Status:
Not filed
Therapeutic Area:
Gastrointestinal Cancer
Manufacturer:
Merck Canada Inc.
Brand Name:
Keytruda
Project Line:
Reimbursement Review
Project Number:
NS0012-000
Submission Type:
Non-submission
Fee Schedule:
N/A
Indications:
Adult patients with unresectable or metastatic microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer whose tumours have progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, as monotherapy.
Recommendation Type:
Canada’s Drug Agency is unable to recommend reimbursement as a submission was not filed by the manufacturer
Last Updated : February 25, 2020